Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?

DSpace/Manakin Repository

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?

Citable link to this page

 

 
Title: Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?
Author: Ok, Chi Young; Ye, Qing; Li, Ling; Manyam, Ganiraju C.; Deng, Lijuan; Goswami, Rashmi R.; Wang, Xiaoxiao; Montes-Moreno, Santiago; Visco, Carlo; Tzankov, Alexandar; Dybkaer, Karen; Zhang, Li; Abramson, Jeremy; Sohani, Aliyah R.; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L.; Hsi, Eric D.; Choi, William W.L.; van Krieken, J. Han; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J.M.; Zhang, Shanxiang; Parsons, Ben M.; Xu, Mina; Møller, Michael B.; Winter, Jane N.; Piris, Miguel A.; Xu-Monette, Zijun Y.; Medeiros, L. Jeffrey; Young, Ken H.

Note: Order does not necessarily reflect citation order of authors.

Citation: Ok, C. Y., Q. Ye, L. Li, G. C. Manyam, L. Deng, R. R. Goswami, X. Wang, et al. 2015. “Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary?” Oncotarget 6 (16): 13933-13945.
Full Text & Related Files:
Abstract: Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546442/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462171
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters